Finch Therapeutics Group Inc. (FNCH)
$7.45
$6.24
(515.70%)
As on 20-May-2026 09:30EDT
Market cap
$15 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
3.1
-
Book Value
$5.7
-
EPS
$-8.6
-
Face value
--
-
Shares outstanding
1,605,763
5 Years Aggregate
CFO
$-222.14 Mln
EBITDA
$-223.97 Mln
Net Profit
$-303.97 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Finch Therapeutics Group (FNCH)
| -- | -- | -- | -- | -5.6 | -55.0 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -9.2 | -7.4 | 6.8 | 8.7 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Finch Therapeutics Group (FNCH)
| -74.9 | -95.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Finch Therapeutics Group (FNCH)
|
7.5 | 14.8 | 5.7 | -13.9 | -346.0 | -86.8 | -- | 0.9 |
| 74.8 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 78.2 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 49.4 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.4 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 7.5 | 8,127.5 | 141.0 | -854.5 | -147.4 | -- | -- | 0.0 | |
| 300.0 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 507.6 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 422.3 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 342.0 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Finch Therapeutics Group (FNCH)
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the... gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. On March 22, 2026, Finch Therapeutics Group, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Chief Executive Officer
Mr. Matthew P. Blischak J.D.
-
Chief Executive Officer
Mr. Matthew P. Blischak J.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Finch Therapeutics Group (FNCH)
What is the current share price of Finch Therapeutics Group Inc (FNCH) Today?
The share price of Finch Therapeutics Group Inc (FNCH) is $7.45 (NASDAQ) as of 20-May-2026 09:30 EDT. Finch Therapeutics Group Inc (FNCH) has given a return of -5.58% in the last 3 years.
What is the current PB & PE ratio of Finch Therapeutics Group Inc (FNCH)?
Since, TTM earnings of Finch Therapeutics Group Inc (FNCH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
-0.08
|
0.25
|
|
2022
|
-0.01
|
0.01
|
|
2021
|
-0.28
|
0.08
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Finch Therapeutics Group Inc (FNCH)?
The 52-week high and low of Finch Therapeutics Group Inc (FNCH) are Rs 7.45 and Rs 7.45 as of 21-May-2026.
What is the market cap of Finch Therapeutics Group Inc (FNCH)?
Finch Therapeutics Group Inc (FNCH) has a market capitalisation of $ 15 Mln as on 15-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Finch Therapeutics Group Inc (FNCH)?
Before investing in Finch Therapeutics Group Inc (FNCH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.